Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Febuxostat 80 mg vs Feburic® in Healthy Thai Volunteers
NCT06233162Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of febuxostat in gout and hyperuricemia (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 24 hours, Maximal measured plasma concentration at 24 hours and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
febuxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06233162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233162.